Prurisol Trial

"Between the subjects already enrolled and those presently in screening, we have reached approximately 70% of theanticipated subjects. Subject recruitment was slower than projected due to competitive trials. In response, we have added additional investigator sites. The Company expects interim analysis top-line results in the third quarter of calendar 2017."

B-UP Trial

"Presently, three patients in the Cohort C, the 200mg dose, have completed their treatment."

Financial Status

"At March 31, 2017, we had $5.6 million in cash. We have expended substantial funds on the research and development of our product candidates."

"As of March 31, 2017, the available balance is approximately $16 million under this stock purchase agreement."

"We anticipate that future budget expenditures will be approximately $14 million over the next 12 months, including approximately $10 million for clinical trials."

Outstanding Shares

131,380,668

https://www.sec.gov/Archives/edgar/data/13552...ix_10q.htm